Genocea raises $35 million for T cell vaccine pipeline
This article was originally published in Scrip
Genocea Biosciences, which is developing T cell-based vaccines, has closed a $35 million series B round of financing. New investors Johnson & Johnson Development Corporation, Skyline Ventures and MP Healthcare Venture Management joined existing investors Polaris Venture Partners, Lux Capital Management, SR One, Cycad Group, Auriga Partners and Morningside Ventures.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.